Ying Zhu

发表

Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study.

B. Massie, W. Abraham, B. Greenberg, 2007, Journal of the American College of Cardiology.

Genetic Predisposition to Severe COVID-19 Might Increase the Risk of Stroke: A Two-Sample Mendelian Randomization Study

F-X Wu, X. Luo, Ying Zhu, 2022, Frontiers in Genetics.

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function

I. Nestorov, T. Marbury, A. Seddighzadeh, 2014, Journal of clinical pharmacology.

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

S. Haeberlein, I. Nestorov, A. Sandrock, 2020, Alzheimer's & Dementia.

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

D. Arnold, P. Calabresi, L. Balcer, 2014, The Lancet Neurology.

A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

I. Nestorov, D. Baker, M. Rogge, 2012, Journal of clinical pharmacology.

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

D. Arnold, P. Calabresi, S. Sheikh, 2015, Multiple sclerosis.

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.

I. Nestorov, D. Baker, M. Panzara, 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report

G. Fan, G. Liu, Hong Zhu, 2021, Anti-cancer drugs.

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study

I. Nestorov, Yue Cui, A. Deykin, 2015, British journal of clinical pharmacology.

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

Peter A Calabresi, Douglas L Arnold, D. Arnold, 2014, BMC Neurology.

PEGylated Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Safety in Subjects with Normal or Impaired Renal Function (P06.165)

A. Seddighzadeh, Xiao Hu, Larisa Miller, 2012 .

Clinical Efficacy and Safety of Peginterferon beta-1a in Relapsing Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S31.006)

D. Arnold, P. Calabresi, L. Balcer, 2013 .

Interim Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S4.005)

D. Arnold, S. Sheikh, B. Kieseier, 2014 .

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

D. Arnold, P. Calabresi, L. Balcer, 2014, The Lancet Neurology.

ADVANCE Phase 3 Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis: Patient Baseline Characteristics (P01.133)

D. Arnold, P. Calabresi, L. Balcer, 2012 .